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ABSTRACT
Objectives: Information on the health care costs associated with nonad-
herence to treatments for diabetes is both limited and inconsistent. We
reviewed and critically appraised the literature to identify the main meth-
odological issues that might explain differences among reports in the
relationship of nonadherence and costs in patients with diabetes.
Methods: Two investigators reviewed Medline, EMBASE, Cochrane
library and CINAHL and studies with information on costs by level of
adherence in patients with diabetes published between January 1, 1997
and September 30th 2007 were included.
Results: A total of 209 studies were identiﬁed and ten fulﬁlled the inclu-
sion criteria. All included studies analyzed claims data and 70% were
based on non-Medicaid and non-Medicare databases. Low medication
possession ratios were associated with higher costs. Important differences
were found in the ICD-9/ICD-9 CM codes used to identify patients and
their diagnoses, data sources, analytic window period, deﬁnitions of
adherence measures, skewness in cost data and associated statistical issues,
adjustment of costs for inﬂation, adjustment for confounders, clinical
outcomes and costs.
Conclusions: Important variation among cost estimates was evident, even
within studies of the same population. Readers should be cautious when
comparing estimated coefﬁcients from various studies because method-
ological issues might explain differences in the results of costs of nonad-
herence in diabetes. This is particularly important when estimates are used
as inputs to pharmacoeconomic models.
Keywords: costs, diabetes, economics, medication adherence, medication
compliance.
Introduction
Nonadherence has a signiﬁcant impact on the cost-effectiveness
of pharmaceuticals [1], and has been estimated to cost the US
economy up to $100 billion per year [2]. In diabetes, nonadher-
ence to oral hypoglycemic medications [3,4] may partly explain
why only 43% of patients with diabetes mellitus have glycosy-
lated hemoglobin (HbA1c) below the 7% level [5,6] recom-
mended by the American Diabetes Association [7].
Studies of adherence in diabetes have focused on its eco-
nomic burden [8–10], its complications [11,12] and the cost-
effectiveness of antidiabetic drugs [13–18]. Many have reported
wide variation in the percent of patients being “nonadherent,”
ranging from 13% to 64% for oral agents and from 19% to 46%
for users of insulin [19–21]. Additionally, important variations in
the coefﬁcient estimations for costs have been reported [21,22],
which might be related to differences in the design, population,
variables included in the analysis and statistical analyses. There-
fore, we reviewed and critically appraised the literature to iden-
tify the main methodological issues that might explain differences
among reports in the relationship of nonadherence and costs in
patients with diabetes.
Methods
Search Strategy
We conducted a systematic literature review using Medline,
EMBASE, Cochrane Library, and the Cumulative Index to
Nursing and Allied Health Literature (CINAHL) from January 1,
1997 to September, 30 2007.
The key terms used included: (compliance, adherence, persis-
tence, nonadherence, concordance) AND (economics, costs,
value, expenditures, resource utilization) AND (diabetes, hyper-
glycemia, diabetes-related complications, antidiabetic medica-
tions, insulin, oral hypoglycemic agents). We also hand-searched
medical journals and reviewed the reference lists of other
reviews.
Selection Criteria
Studies that reported costs by different levels of medication
adherence or persistence were included. Adherence and persis-
tence deﬁnitions were according to previous studies [23]. We also
included studies that used HbA1c as a proxy of medication
adherence because HbA1c is a well-established measure of gly-
cemic control [22,24,25] and a proxy for adherence [26]. Non-
English studies, articles with insufﬁcient data, and those without
costs or adherence information were excluded.
Extracted Information
Abstracts and full publications were reviewed by two researchers
and disagreements were resolved by consensus. The extracted
information included the study design, data source(s), methods
of adherence measurement, statistical analysis, and results. Study
designs were classiﬁed as trials, cohort, case-control, or cross-
sectional studies. Data sources for patient demographics, adher-
ence, resource utilization, and costs, as well as observation and
follow-up periods, were recorded (Table 1). For statistical analy-
sis, we included information on any statistical method used
to assess the relationship or association between medication
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nonadherence and costs, sample size, adjustment for inﬂation
and/or discounting, adjustment for confounders or for the days
when patients were in institutionalized care settings such as
hospital, and nursing home (Table 2).
Quality Criteria
A checklist for economic evaluation [27] was modiﬁed to assess
the quality of studies. The original checklist contained 35 items,
but 5 of them were related to health economic models (12, 14 15,
20, and 21), and were not considered applicable to the studies
included in the review. We assigned a score of 1 if an article
included the required item, and zero if it was not included.
Therefore, the maximum score for an article that included all
information related to study design, data collection, analysis and
interpretation of results was 30.
Results
Search Results
Two hundred nine titles were identiﬁed and their abstracts were
reviewed. Fifty abstracts included information on both adherence
and costs in patients with diabetes, and their full articles were
retrieved. Ten studies [17,28–36] fulﬁlled the inclusion criteria
(Fig. 1). All studies analyzed US claims data using retrospective
cohort studies designs [17,28–36] (Table 1). Three studies
utilized Medicare or Medicaid databases [28,30,32], while
all others used commercial or managed care organizations data
sets.
Association between Medication Nonadherence
and Cost
There were important variations in the items included in order to
estimate costs. For example, one study included only claims for
physician ofﬁce visits, outpatient services, and hospital stays [29],
while another was more comprehensive, and included: costs
for hospitalization, outpatient care, emergency care, clinic visits,
laboratory tests, professional services, and pharmaceuticals [31].
Two studies took into account the net cost to the plan but they
did not include patients’ copayments and deductibles [33,35],
while a third study included copayments and deductibles [36].
The study by Wagner used its own internal accounting system
that included overhead costs [34]. It was unclear in some studies
as to which speciﬁc costs were included [17,28,32].
Low medication possession ratios (MPRs) were generally
associated with higher costs. For example, one study reported an
association of MPR of 60% with mean total costs of $8699 [29].
Balkrishnan et al. found that a 10% increase in MPR for an
antidiabetic medication was associated with an 8.6% reduction
in total annual health care costs [28]. Studies generally reported
increments of mean annual costs according to baseline HbA1c
values. For example, the mean annual costs for patients with
baseline HbA1c < 8% were $4475, while for those with
HbA1c > 10 were $8088 [34] (Table 2).
Methodological Issues
The speciﬁc International Classiﬁcation of Diseases (ICD-9) or
ICD-9 Clinical Modiﬁcation (ICD-9-CM) codes used to identify
the study population were not mentioned in three studies
[30,34,35], and among those that were reported, there were
important variations in the codes included (Tables 1 and 2). For
example, some studies included type 1 and type 2 diabetes
[28,31,33], while others excluded type 1 diabetes [17,29,36].
The population varied by study, as well by period of observation.
The maximum follow-up was 5 years, and half of the studies
followed patients for only 1 year.
Table 2 presents measures of adherence, costs, statistical
analysis, results of each study, and quality score. All studies used
claims data to collect drug utilization information. Five studies
used MPR as a measure of medication adherence [17,28–30,32],
two studies did not report a speciﬁc medication adherence
measure [34,36], and three used various measures of medication
adherence such as medication adherence rate [31], percentage
days supplies [33], and percentage of adherence [35]. All studies
used the total follow-up period to calculate adherence and costs,
and used charges as proxy for costs. In terms of type of costs,
some studies reported total health-care costs [17,28–30,34–36],
while others focused on overall costs of health care [31], or costs
related with diabetes care [32,33]. Two studies used Poisson
regression models for costs [17,29], and the remainder used
multivariate regression analysis for costs. Few studies log-
transformed costs [32,34,36], and only one study [22] tried to
deal with the skewed distribution of both health-care costs and
MPRs. Seven studies were able to adjust for some potential
confounders [17,28,29,31–33,36], while only one adjusted costs
for inﬂation and duration of hospitalizations [28]. Most studies
were assigned a low quality score (<50% of required informa-
tion), ranging from 8/30 to 14/30.
Discussion
We identiﬁed various methodological issues that hinder compari-
sons from being made across studies, and which might result in
signiﬁcant differences in the reported associations between non-
adherence to medicines and costs in patients with diabetes.
Based on the International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) recommendations on improv-
ing the quality of adherence studies [37,38], we found that the
type of study design was not clearly established, and studies were
unable to distinguish prevalent from incident cases. Incident
cases are more expensive than prevalent cases in terms of hospi-
talization rates, length of stay, case mix, and service intensity, and
have higher discontinuation rates [39–41]. Studies included dif-
ferent population groups, which has an impact on costs: some
focused on codes for type 2 diabetes only, type 1 and type 2,
gestational diabetes, and/or diabetes-related complications. For
example, gestational diabetes is more expensive than type 2
diabetes because of the frequency and duration of hospitaliza-
tions [42]. None of the studies described if primary, secondary, or
both codes were used. Previous studies have shown an increase in
costs by up to twofold when both primary and secondary ICD-9
codes were used [31].
Contrary to accepted recommendations, none of the studies
validated ICD-9/ICD-9-CM codes [43]. Wilchesky et al. showed
64% sensitivity of claims data to detect patients with diabetes
[44], which means that an appreciable number of cases may be
missed. Similarly, none of the studies validated prescription
claims data that are vulnerable to errors from sampling, misiden-
tiﬁcation of newly treated patients, and misclassiﬁcation of
added versus switched medications [45,46]. ICD-9/ICD-9-CM
codes to measure utilization and costs also requires validation,
because some studies have found that 9% of discharges incor-
rectly omit codes for diabetes, and 13% of discharges are regis-
tered without any foot-related diagnosis code [47].
Most studies used medication possession ratios, but there
were important variation in the deﬁnition. For some, MPR was
the sum of days of antidiabetic prescription supply dispensed
divided by the number of days between prescription reﬁlls, from
the ﬁrst date of dispensing within each year until the dispensing
Costs of Nonadherence in Diabetes Mellitus 917
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date of the last prescription [28,32]. Others added the days’
supply of the last reﬁll to the denominator [17,29], or they used
the percentage of days that the patient possessed any available
diabetic drug during the year [31]. None of the studies consid-
ered the effects of censoring, which is important, because six
ﬁlled prescriptions evaluated over 12 months equals an MPR of
50%, but if they are evaluated over 6 months, the six ﬁlled
prescriptions equals an MPR of 100%.
The non-MPR measures included were: Med-total approach
deﬁned as the ratio of total number of days the drug was supplied
to the difference in the number of days between the ﬁrst and last
prescription dates [32]; the percentage of days during the analysis
period that patients had a supply of one or more maintenance
medications for the condition [33], and the percentage of adher-
ence [35]. The problem is that these measures are not compa-
rable. Hess [48] analyzed various adherence measures and found
that only 4—Continuous Measure of Medication Acquisition;
Continuous Multiple Interval Measure of Oversupply; MPR; and
Medication Reﬁll Adherence—out of 11 measures were identical
for measuring adherence to prescription reﬁlls throughout the
study period.
With regard to confounders, 6 out of 10 studies made some
effort to adjust their estimates by disease severity, but most did
not adjust by comorbidities, thereby potentially underestimating
the real costs. None of the databases used by analysts contain
information of behavioral variables such as smoking and alcohol
that are closely related to adherence [49–53]. There was also lack
of information on adverse drug events, such as hypoglycemia,
which has been shown to be a costly component of diabetes-
related treatment [54]. None of the studies were able to measure
the direct consequences of either nonadherence (e.g., hyperosmo-
lar coma) or associated utilization-based outcomes. Costs were,
therefore, not disaggregated according to the main drivers
that are a consequence of loss of therapeutic effect through
nonadherence.
All studies used charges as proxy for costs. However, charges
have been criticized because they do not reﬂect real costs [55],
and they do not take into account the various levels of copay-
ment, deductibles, and coinsurance for prescriptions and other
medical services, including physician ofﬁce care, medical emer-
gency care, and inpatient hospitalization.
Only one study tried to deal with skewed distribution of
health-care costs and MPR [22]. This is important, because inap-
propriate analysis of costs will produce biased estimates for the
mean. For costs, nonparametric bootstrap techniques or GLM
regression analyses are recommended [56,57].
Conclusion
The research assessing the association between medication
adherence/nonadherence and health-care costs is limited and of
poor quality. There are important methodological differences
among studies of costs of adherence/nonadherence in patients
with diabetes, making robust comparisons difﬁcult; and those
differences might explain the inconsistency in the reported
associations between medication adherence and costs. Readers
should be cautious when interpreting or comparing the results of
such studies. More research is needed to validate measures of
medication adherence using claims data and to determine the
impact of nonadherence on health-care costs.
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